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Deﬁning consensus leukemia-associated immunophenotypes for
detection of minimal residual disease in acute myeloid leukemia
in a multicenter setting
N Feller1, VHJ van der Velden2, RA Brooimans3, N Boeckx4,5, F Preijers6, A Kelder1, I de Greef7, G Westra1, JG te Marvelde2,
P Aerts3, H Wind2, M Leenders6, JW Gratama3 and GJ Schuurhuis1
Flow-cytometric detection of minimal residual disease (MRD) has proven in several single-institute studies to have an independent
prognostic impact. We studied whether this relatively complex approach could be performed in a multicenter clinical setting. Five
centers developed common protocols to accurately deﬁne leukemia-associated (immuno)phenotypes (LAPs) at diagnosis required
to establish MRD during/after treatment. List mode data ﬁles were exchanged, and LAPs were designed by each center. One center,
with extensive MRD experience, served as the reference center and coordinator. In quarterly meetings, consensus LAPs were
deﬁned, with the performance of centers compared with these. In a learning (29 patients) and a test phase (35 patients), a mean
of 2.2 aberrancies/patient was detected, and only 1/63 patients (1.6%) had no consensus LAP(s). For the four centers without
(extensive) MRD experience, clear improvement could be shown: in the learning phase, 39–63% of all consensus LAPs were missed,
resulting in a median 30% of patients (range 21–33%) for whom no consensus LAP was reported; in the test phase, 27–40% missed
consensus LAPs, resulting in a median 16% (range 7–18%) of ‘missed’ patients. The quality of LAPs was extensively described.
Immunophenotypic MRD assessment in its current setting needs extensive experience and should be limited to experienced
centers.
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INTRODUCTION
The interest in minimal residual disease (MRD) assessment as a
prognostic tool in acute myeloid leukemia (AML) is growing.
Molecular markers, although allowing a greater sensitivity, enable
MRD monitoring only in a minority of cases.1 Immunophenotypic
MRD detection using ﬂow cytometry turned out to offer an
attractive alternative. Using immunophenotyping, several early
studies have shown the prospective value of the frequency of
MRD cells for survival of AML patients both in adults2–6 and in
children.7–9 Meanwhile, many other studies have conﬁrmed these
data.1,10 Immunophenotypic detection of MRD using ﬂow
cytometry can be performed by deﬁning aberrant expression of
markers or marker combinations on the leukemic cells at diagnosis.
These so-called leukemia-associated (immuno)phenotypes (LAPs)
are absent, or are present at very low frequencies, in normal blood
or bone marrow (BM) cells. This approach can be successfully
applied in 80–100% of AML patients.2–9,11
Apart from serving as a prognostic marker, MRD may ultimately
turn out to offer a tool to guide patient-tailored therapy, an
approach already adopted once for childhood AML.12 Even when
categorized as low risk by cytogenetics/molecular markers and/or
other conventional prognostic parameters, AML patients may be
identiﬁed to be at high risk based on MRD cell frequency after
induction therapy and stratiﬁed to treatment intensiﬁcation such
as allogeneic transplantation. Inversely, intensive treatment in AML
patients deﬁned as ‘poor risk’ by conventional factors, but as ‘low
risk’ based on MRD assessment, might ultimately be avoided.
Furthermore, at follow-up, increments in MRD cell frequency by
sequential MRD assessments may identify forthcoming relapses, in
turn urging therapy to be administered before overt relapse occurs.
For these reasons, it is important to establish the prognostic
value of MRD cell frequency assessment in clinical studies in
prospective, multicenter settings. A ﬁrst requirement to enable
adequate performance of such studies is the standardization of all
procedures necessary for deﬁnition of adequate LAPs in newly
diagnosed AML, as well as those necessary for identiﬁcation and
quantiﬁcation of MRD in BM follow-up material. Standardizing LAP
technology for MRD detection is complicated because aberrant
immunophenotypes may not only differ from patient to patient
but also within a patient, often resulting in many different LAPs
(illustrated in Supplementary Figure 1). There are large differences
in the suitability of LAPs. This suitability may be deﬁned by at least
four factors. First, the percentage of blasts that bear a particular
aberrancy at diagnosis determines the sensitivity of subsequent
detection and quantiﬁcation of AML cells. Second, the extent to
which equivalent cells in control normal BM bear the aberrancy
determines LAP speciﬁcity: the lower the frequencies of such
‘background’ expression, the higher the LAP speciﬁcity.5,13,14 Third
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is the stability of LAPs at follow-up—that is, the possibility that
expression of markers, which constitute the LAP, may be higher or
lower at follow-up as compared with diagnosis,5,14–16 thereby
resulting in overestimation or false negativity, respectively, of
MRD. Finally, the quality of monoclonal antibody conjugates, as
well as the stability and resolution of the ﬂow cytometer, is
important. All these factors contribute to, often, large differences
in the applicability of speciﬁc LAPs for different leukemia cases.
To standardize all the procedures that are needed for LAP
deﬁnition as well as for quantiﬁcation of MRD, ﬁve centers in
Belgium and the Netherlands joined forces in 2004. These centers
had ample experience in (at least) four-color ﬂow cytometry. One
of these centers had extensive experience with MRD detection in
adult AML and served as the reference and coordinating center.
The primary goal of this study was to standardize the
identiﬁcation of LAP at diagnosis. First, we deﬁned a standardized
antibody panel and standard operating procedures based on both
the MRD experience in the group, the published data and
extensive knowledge of the performance of antibody conjugates.
Second, we evaluated whether this standardized antibody panel
could identify robust LAPs in the vast majority of AML patients.
The quality of LAPs was determined on the basis of their
presumed speciﬁcity, sensitivity and stability. The coordinating
center served as reference for the deﬁnition of LAPs. Finally, the
(improvements in) performance of individual laboratories in
identifying LAPs in an initial learning phase and a test phase
was evaluated.
MATERIALS AND METHODS
Patients and cells
Sixty-four patients with AML, consecutively presenting during a period of
18 months (July 2004–December 2005) in the participating institutes, were
included. The median age was 59 years (range: 9–85; two children of 9 and
15 years were included). FAB (French-American-British) classiﬁcation
distribution was 6 M0, 11 M1, 16 M2, 2 M3, 6 M4, 5 M5, 3 M6, 1 M7, 6
RAEB (3 RAEB and 3 RAEB-t), 1 secondary AML (out of CML), 1 AML with
non-Hodgkin’s lymphoma and 6 cases with unknown classiﬁcation. BM of
patients with AML, and normal BM from patients with cardiac disease, was
obtained after informed consent and according to the institutional
protocols. LAPs in normal BM controls were deﬁned as percentages of
white blood cells (WBCs).
Participating centers and working plan
The participating centers were required to have the following criteria:
(i) longstanding experience in immunophenotyping of leukemia using at
least four-color ﬂow cytometry; (ii) access to clinical samples;
(iii) experience either in MRD assessment and/or in quantiﬁcation of
low-frequency cell subpopulations; (iv) participation for at least 5 years in
external quality control assessment programs for CD34 counting
and leukemia/lymphoma immunophenotyping;17,18 and (v) extensive
experience with various antibody–ﬂuorochrome combinations. Five
centers from the Netherlands and Belgium participated (for details, see
Supplementary Files). Amsterdam (indicated as no. 1) served as the
coordinating and reference center, and the other centers were anon-
ymously, in arbitrary sequence, referred to as participants no. 2–5.
Four centers were equipped with a FACScalibur (Becton Dickinson,
San Jose, CA, USA) with an argon and red diode laser. CellQuest software
was used for analyses of the list mode data (LMD). One participant was
equipped with a Beckman Coulter ﬁve-color FC500 ﬂow cytometer (Miami,
FL, USA) with an argon laser. LMD were analyzed with CXP software
(Miami, FL, USA).
The study period was subdivided in two phases: a learning phase with
28 patients and a test phase with 35 patients (for details, see
Supplementary Files).
Immunophenotypic labeling
The ﬁrst goal of the working group was to develop a standard panel of
monoclonal antibody combinations to deﬁne putative LAPs at diagnosis.
This panel was composed of monoclonal antibodies and ﬂuorochromes in
four-color combinations based on previous experience with LAP deﬁni-
tions and MRD assessments in AML,5,19 as well as extensive knowledge of
antibody–ﬂuorochrome performance. MoAbs were conjugated with
ﬂuorescein isothiocyanate, phycoerythrin (PE), peridinyl chlorophyllin or
allophycocyanin for FACSCalibur users, and with ﬂuorescein isothiocya-
nate, PE, phycoerythrin-Texas Red conjugate (energy coupled dye, ECD)
and PE-Cy5 for the Coulter FC500 user (Table 1). The backbone of a LAP
consists of CD45, a primitive marker (CD34, CD133 or CD117), a myeloid
marker (usually CD13 or CD33) and one of the aberrant markers listed in
Table 1. The antibody–ﬂuorochrome combinations were centrally pur-
chased, titrated and diluted to the user concentration, and subsequently
distributed to all centers.
LAPs were established in newly diagnosed AML in a two-step approach. In
the ﬁrst step, the panel was used to deﬁne the immunophenotype of the
blasts in whole BM or peripheral blood at diagnosis. In this so-called ﬁrst run,
aberrant expression patterns of individual markers were deﬁned, and, from
these, relevant markers for the putative LAPs for MRD assessment (one LAP
per tube) were deﬁned. As these markers may originate from different tubes,
the ﬁnally chosen combinations had to be tested in a so-called second run.
Because of the large number of LAPs, central distribution of conjugate
combinations for the second run was not feasible.
For all relevant monoclonal antibodies, the experience of all centers
(advantages, disadvantages and pitfalls) was evaluated in regular meetings
of the study group. The ﬁnal list of antibody–ﬂuorochrome combinations
for use in the second run is shown on the website http://www.vumc.
nl/afdelingen/hematologie/behandelaars/onderzoek/ under ‘clones of
monoclonal antibodies’.
Data exchange and data interpretation
When a patient was included in the study in one of the ﬁve institutes, the
procedure of data exchange was as follows: the LMD of the ﬁrst run were
uploaded by that institute to a website (termed ‘X-drive’), with accessibility
restricted to the working group members (Figure 1). Using this site, each of
the ﬁve institutes analyzed these ﬁrst run LMD ﬁles of that particular
patient and, independent of each other, deﬁned putative LAPs. These were
communicated to the coordinator. From all putative LAPs, the coordinator,
according to its experience, deﬁned so-called ‘proposed LAPs’, fulﬁlling as
many essential criteria as possible. In the quarterly group meetings, these
‘proposed LAPs’, upon consensus, were termed ‘consensus LAPs’. On some
occasions, the consensus LAPs deviated from the proposed LAPs. Also, all
other putative LAPs were discussed, with performance evaluated for all
individual centers.
Table 1. Standard immunophenotypic panel
Tube FITC/FITCa PE/PEa PerCP/ECDa APC/PE-CY5a
1 PBS PBS CD45 PBS
2 CD34 CD22 CD45 CD117
3 CD15 CD13 CD45 CD14
4 HLA-DR CD33 CD45 CD11b
5 CD2 CD56 CD45 CD7
6 TdT/CD36 CD133 CD45 CD19
Abbreviations: APC, allophycocyanin; ECD, energy coupled dye; FITC,
fluorescein isothiocyanate; PBS, phosphate-buffered saline; PE, phycoery-
thrin; PerCP, peridinyl chlorophyllin. Before use, monoclonal antibodies
were centrally titrated, diluted to working solutions and distributed to the
participating institutes. The first tube, containing CD45 in FL3 and PBS in
the other channels, was used to discriminate between absence and
presence of marker expression. During the test phase of the study, TdT
was replaced by CD36. Below is indicated per fluorochrome the antibody
clone from BD/antibody clone from Immunotech (markers are in bold for
reasons of clarity). In case of other suppliers, these are indicated in between
parentheses. FITC: CD34: 8G12/581; CD15: MMA/MMA; HLA-DR: L243/
im.357; CD2: S5.2/39C1.5; TdT: HT-6 (DAKO)/HT-6 (DAKO); and CD36: FA6-
152/CLB 703 (CLB). PE: CD22: S-HCL-1/SJ10.1H11; CD13: SJ1D1/SJ1D1; CD33:
P67.6/D3HL60.251; CD56: NCAM16.2/NCAM16.2; and CD133: CD133/2
(Miltenyi)/CD133/2 (Miltenyi). PerCP/ECD: CD45: 2D1/J33. APC/PE-CY5:
CD117: 104D2/104D2D1; CD14: MoP9/RM052; CD11b: D12/Bear 1; CD7:
M-T701/8H8.1; and CD19: SJ25C1/J4.119. aFluorochrome used for BD FCM/
fluorochrome used for Beckman Coulter FCM.
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Statistics
Student’s t-test was used to evaluate the signiﬁcance of improvements in
performance between the learning and test phases of the study.
RESULTS
Standard immunophenotypic panel (ﬁrst run)
After the learning phase, tube 6 was modiﬁed: TdT was replaced
by CD36, as TdT had not contributed to suitable independent
LAPs, did not appropriately function as an exclusion marker for M4
and M5 AML types, and, as intracellular marker, hampered a rapid
application of the panel.
In the next ﬁve sections, the performance of the panel (number
and nature of LAPs detected and the sensitivity, speciﬁcity and
stability of consensus LAPs) is described. This part covers the ﬁnal
results after the consensus meetings. Finally, performance of
individual centers in both phases is described.
Number and nature of consensus LAPs
In the learning phase, 55 consensus LAPs were found in 28 patients
(Tables 2a and b, third column). No LAPs were found in one patient
(3.5%). In the test phase, 88 consensus LAPs were found in 35
patients (Tables 2a and b, fourth column). LAPs were found in all
patients. For details on numbers of LAPs per patient per study
phase, see legends of Table 2. Taken together, one or more LAPs
could be identiﬁed in almost all AML patients (63/64: 98.5%).
Table 3 shows a detailed overview of consensus LAPs, divided
into the well-known four major groups. Important are LAPs that
were chosen most frequently as the best (that is, most sensitive and
most speciﬁc, and stable, as outlined in the next paragraphs).
Table 3 shows the leading aberrancies in the ﬁrst column, with, in
the fourth column (printed in boldface), the percentage of patients
for whom these aberrancies were chosen as best consensus LAPs.
These included cross-lineage expression with CD7 as the leading
marker (36% of the patients), asynchronous expression of CD34 and
CD133 (20%), asynchronous expression of CD15 combined with a
progenitor marker (28%) and absence of HLA-DR (20%) or CD33
(11%) in combination with a progenitor marker. All other
aberrancies were considered suitable in o10% of the patients.
In 60 of the 64 patients, at least one primitive marker (CD34,
CD117 or CD133; more details about distribution in legends of
Table 3) was present in the consensus LAPs. The remaining four
cases had LAPs without a primitive marker (three patients), or no
LAP at all (one patient).
Sensitivity of the consensus LAPs
LAPs were categorized into the following three groups based on
the percentage of LAP-covered leukemic cells (Table 2): (1)450%
(sensitivity category ‘high’); (2) 20–50% (‘intermediate’); and
(3) 10–20% (‘low’). LAPs present on o10% of blast cells were
not considered suitable for MRD monitoring.
Table 2a shows for all consensus LAPs that the best sensitivity
category (‘high’) contained 64% (51þ 13%) and 50% (42þ 8%) of
the LAPs in the learning phase and test phase, respectively. Taking
Putative LAPs
X-drive
Other Center Other Center Other Center Other Center
Putative LAPsPutative LAPsPutative LAPsPutative LAPs
E-mail E-mailE-mailE-mail E-mail
Coordinating
Center Proposed LAPs
Proposed LAPs
Final LAP(s) for MRD
Consensus LAPs
Consensus meetings
Any of the centers: diagnosis 1st run LMD files
Figure 1. Organization of the study. When any of the five centers
entered an AML patient (top of the figure), it ran the monoclonal
antibody panel shown in Table 1 and sent the LMD to the other
centers. All centers then formulated their putative LAP(s) and sent
these to the coordinator, who subsequently designed ‘proposed
LAP(s)’. Finally, at the quarterly group meetings, ‘consensus LAP(s)’
were agreed upon, and ‘final LAPs’ were formulated for subsequent
MRD studies.
Table 2. Consensus LAPs in terms of sensitivity and specificity
A
Sensitivitya (%) Specificitya Number of consensus LAPsb,
(% of total, in specific phase)c
Learning phase Test phase
450 (high) High 28 (51) 37 (42)
Low 7 (13) 7 (8)
20–50 (intermediate) High 13 (24) 29 (33)
Low 2 (4) 6 (7)
10–20 (low) High 4 (7) 6 (7)
Low 1 (2) 3 (3)
Total 55 (101) 88 (100)
B
Sensitivitya (%) Specificitya Number of best consensus LAPsb
(% of total, in specific phase)
Learning phase Test phase
450 (high) High 18 (64) 18 (51)
Low 2 (7) 3 (9)
20–50 (intermediate) High 5 (18) 12 (34)
Low 1 (4) 1 (3)
10–20 (low) High 1 (4) 1 (3)
Low 1 (4) 0 (0)
Total 28 (101) 35 (100)
Abbreviation: LAP, leukemia-associated (immuno)phenotype. LAPs are
defined by the following preference: first, LAPs with the highest sensitivity
(450% expression) and best specificity (o0.1% background) are denoted
as ‘high/high’, and with decreasing preference, this is followed by
‘intermediate/high’, ‘high/low’, ‘low/high’, ‘intermediate/low’ and, lastly,
‘low/low’. aLAPs were categorized as a function of sensitivity (‘high’,450%
expression; ‘intermediate’, 20–50% expression; and ‘low’, 10–20% expres-
sion by the leukemic blasts) and specifitity (‘high’,o0.1% background; ‘low’,
X0.1% background). bIn A, total number of consensus LAPs are denoted,
with percentages of total number in learning or test phase; in B, total
number total number of best consensus LAPs per patient (which thus
equals the number of patients) are denoted, with percentages of total
number in learning or test phase. cIn learning phase, no LAPs were found
in one patient (3.5%), one LAP in 38%, two LAPs in 41%, three LAPs in 0%,
four LAPs in 14% and five LAPs in 3.5% of the cases (not shown in the
table). In test phase, LAPs were found in all patients: one LAP in 28%, two
LAPs in 26%, three LAPs in 17%, four LAPs in 23% and five LAPs in 6% of
the cases (not shown in the table).
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the high and intermediate categories together, these ﬁgures were
92% and 90%, respectively.
On performing the same analysis for the best consensus LAP
(total number is 63, similar to the number of patients with LAP), it
was seen that the high category contained in the learning phase
71% of the LAPs and in the test phase 60% of the LAPs. Taking the
high and intermediate categories together, these ﬁgures were
93% and 97%, respectively (Table 2b).
Speciﬁcity of the consensus LAPs
The speciﬁcity of a LAP depends on the expression of the aberrant
immunophenotype on normal myeloid progenitor and/or mature
cells. All participants evaluated the background of the consensus
LAPs in normal BM. The median expression on normal myeloid
cells usually was o0.05% (% of WBC), with maximum values
generallyo0.1% (Figure 2). This background resulted mainly from
aberrant expression on the immature population: LAPs with an
immature marker, which represent the vast majority of all
consensus LAPs (87%) and of all best consensus LAPs (95%), had
up to 10% background aberrancies on the immature population
(Figure 2b). CD36 on WBC and on primitive cells was discovered
during the study to have higher percentages (Figures 2a and b)
and thereafter excluded from further analysis. In LAPs without
primitive markers (only 13% of all consensus LAPs and 5% of best
consensus LAPs), median LAP expression on normal BM WBC was
usually o0.1% (data not shown).
The speciﬁcity of a consensus LAP was now categorized as
(1) ‘high’ (o0.1% background) or (2) ‘low’ (X0.1% background). The
two speciﬁcity categories are presented in Table 2a and distributed
over the three sensitivity categories. The high-speciﬁcity category
contained in the learning phase 82% (51þ 24þ 7%) and in the test
phase 82% (42þ 33þ 7%) of all consensus LAPs.
On performing the same analysis for the best consensus LAP
(total number 63), it was seen that the highest speciﬁcity category
represented 86% of the patients in the learning phase and 88% in
the test phase (Table 2b).
Table 3. Summary of consensus LAPs
Aberrant immunophenotypes Number
of cases
% of
total
number
of LAPs
Used as best
consensus
LAPs (% of
patients)a
LAPs with immature markers (n¼ 125)b
Cross-lineage antigen expression (n¼ 42) n¼ 42 29.4
CD7 26 18.2 36
CD34þ MMþ CD7þ 11
CD117þMMþCD7þ 8
CD34þCD117þCD7þ 3
CD117þCD133þCD7þ 3
CD34þCD133þCD7þ 1
CD22 6 4.2 o10
CD34þ MMþ CD22þ 4
CD117þ MMþ CD22þ 1
CD34þ CD133þ CD22þ 1
CD56 5 3.5 o10
CD34þ MMþ CD56þ 4
CD133þ MMþ CD56þ 1
CD19 3 2.1 o10
CD117þ MMþ CD19þ 2
CD34þ MMþ CD19þ 1
CD2 2 1.4 o10
CD34þ MMþ CD2þ 1
CD34þ CD117þ CD2þ 1
Asynchronous antigen expression (n¼ 73)c n¼ 73 51,0
CD34neg CD133þ 14 9.8 20
CD34neg CD133þ CD117þ 13
CD34neg CD133þ þ CD33þ 1
CD15 19 13.2 28
CD34þ MMþ CD15þ 7
CD133þ MMþ CD15þ 4
CD117þ MMþ CD15þ 3
CD34þ CD133þ CD15þ 3
CD133þ MMþ CD15þ 1
CD117þ MMþ CD15þ 1
CD13neg 9 6.3 o10
CD34þ CD117þ CD13neg 4
CD133þ MMþ CD13neg 2
CD34þ CD133þ CD13neg 1
CD34þ MMþ CD13neg 1
CD117þ MMþ CD13neg 1
HLA-DRneg 8 5.6 20
CD34þ CD117þ HLA-DRneg 4
CD34þ MMþ HLA-DRneg 2
CD133þ CD117þ HLA-DRneg 1
CD117þ MMdim HLA-DRneg 1
CD33neg 7 4.9 11
CD34þ MMþ CD33neg 7
CD36þ (see legend) 6 4.2 See legends
CD34þ CD117þ CD36þ 3
CD34þ CD133þ CD36þ 1
CD133þ MMþ CD36þ 1
CD117þ CD34neg CD36þ 1
CD11bþ 5 3.5 o10
CD117þ MMþ CD11bþ 4
CD34þ MMþ CD11bþ 1
CD15negHLA-DRnegCD117þCD34neg 4 2.8 o10
CD15negHLA-DRnegCD117þCD34neg 4
CD45neg 1 0.7
CD13þCD33þCD45negCD117þ 1
Overexpression (n¼ 10) n¼ 10 7.0 o10
HLA-DRþ þ 4 2.8 o10
CD117þ CD34neg HLA-DRþ þ 2
CD34þ MMþ HLA-DRþ þ 1
CD117þ CD36neg HLA-DRþ þ 1
CD13þ þ 4 2.8 o10
CD34þ CD133þ CD13þ þ 2
CD34þ CD117þCD13þ þ 2
CD33þ þ 1 0.7 o10
CD34þ CD117þ CD33þ þ 1
CD34þ þ 1 0.7 o10
CD117neg CD19negCD34þ þ 1
LAPs without immature markers (n¼ 18) n¼ 18 12.6
CD13neg 8 5.6 o10
CD15þCD14negCD13neg 5
CD15þCD34negCD13neg 1
CD15þCD33þCD13neg 1
CD11bþHLA-DRþCD13neg 1
CD56 3 2.1 o10
CD15þCD33þCD56þ 1
CD14negCD33þCD56þ 1
HLA-DRþCD33þCD56þ 1
CD14neg 2 1.4 o10
CD15þCD13þCD14neg 1
CD11bþHLA-DRnegCD14neg 1
HLA-DRneg 2 1.4 o10
CD15negCD13þHLA-DRneg 1
CD11bþCD36-DRneg 1
HLA-DRþ 1 0.7 o10
CD15þCD33þHLA-DRþ 1
Table 3. (Continued )
Aberrant immunophenotypes Number
of cases
% of
total
number
of LAPs
Used as best
consensus
LAPs (% of
patients)a
CD22 1 0.7 o10
CD33þHLA-DRþCD22þ 1
CD33dim 1 0.7 o10
CD34negCD13þCD33dim 1
Totald 143 100
Abbreviations: LAP, leukemia-associated (immuno)phenotype; MM,
myeloid marker (usually CD13 or CD33, depending on diagnostic
phenotype). LAPs identified in the 64 BM samples using the standard
immunophenotyping panel. The mean number of LAPs per patients is 2.2
(143 LAPs/64 patients). In only one sample, no LAP could be defined. A
primitive marker (CD34, CD117 or CD133) was included in 125 of 143 (87%)
of the LAPs. a‘Best consensus LAP’ is defined as the LAP with highest
sensitivity and specificity (see Results). More than one LAP may fulfill the
same requirement, thereby defining more than one best consensus LAP
per patient. As a result in the column used as ‘best consensus LAP (% of
patients)’, the total percentages exceed 100%. bCD34 alone was used in
42%, CD117 alone in 27% and CD133 alone in 5%, although any of the four
possible combinations of at least two primitive markers were used in 18% of
the cases (data not shown). In the latter cases, it was often possible to
define for the same patient at least two LAPs based on different primitive
markers. cLAPs with underexpression (usually absence) of markers were
almost exclusively present in the group with asynchronous expression
(data not shown) and not separately scored. dAs two or more consensus
LAPs were identified in many patients, the total number of consensus LAPs
(i.e., 143) exceeded the total number of patients (i.e., 64).
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Combined analysis of sensitivity and speciﬁcity
Ultimately, the quality of the consensus LAP has to be acquired on
the combined evaluation of sensitivity and speciﬁcity. The best LAP
possesses the highest sensitivity (450% expression) and the best
speciﬁcity (o0.1% background). The order of quality of other LAP
categories is presented in the legends of Table 2. Assuming that
the high- and intermediate-sensitivity categories, together with
high speciﬁcity, will offer the best consensus LAPs (63 in total),
Table 2b shows that in 82% (64þ 18%) of cases in the learning
phase and in 85% (51þ 34%) in the test phase, LAPs met this
demand (further details are in Supplementary Files). It can thus be
concluded that, in the majority of the 63 evaluable patients,
relatively high-quality (420% expression ando0.1% background
reactivity) LAPs can be designed.
Stability of LAPs
Scoring for a good LAP based on stability did not include a
learning and test phase, but it was performed using a list of
expression of markers in paired diagnosis–relapse samples. We
have performed an extensive comparison between diagnosis and
relapse in 33 AML patients (18 different antigens in 125 diagnosis–
relapse comparisons; Supplementary Table 1). In general, LAPs are
relatively stable in most cases with a notable exception for CD19.
For details, see Supplementary Results and Supplementary
Table 1.
Performance of individual centers
The data discussed above constitute the ﬁnal outcome of all
consensus meetings. Next, we describe the performance of
individual centers.
Missed LAPs. In the learning phase, centers 2–5 missed 39–63%
of the consensus LAPs, whereas the coordinator (no. 1) missed
11% (Table 4). In the test phase, these percentages dropped to
27–40% and 3%, respectively (Table 4). Thus, the improvement
was 12–33% for centers 2–5 and 8% for the coordinator.
Supplementary Figure 2 shows a detailed overview of the
numbers of missed LAPs per institute per phase.
Number of patients with no second LAP deﬁned; comparison
between the institutes. We then studied how many patients
would not have been eligible for follow-up evaluation because of
the missing of all LAPs present. For a patient to be eligible for MRD
evaluation, at least one consensus LAP should have been deﬁned.
The answer, based on the data in Supplementary Figure 2, has
been summarized in Figure 3a: in the learning phase, the
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Figure 2. Aberrant expression of marker/marker combinations on WBC and immature cell fractions in normal BM. Different LAP
immunophenotypes tested in normal BM. All LAPs contained CD45 and, if not indicated in the figure, a myeloid marker (CD13 or CD33) or
CD117. (a) LAP expression as % of WBC. Note the relatively high expression of CD34þCD36þ . (b) Aberrant marker expression as a percentage
of primitive marker compartment (CD34 or CD117). Note logarithmic scale in a and b.
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percentages of patients apparently ineligible for MRD detection
ranged from 21 to 33% for centers 2–5, whereas the coordinator
identiﬁed at least one LAP in all. In the test phase, results clearly
improved: the percentages of patients without any identiﬁed LAP
ranged from 7 to 18%, whereas the coordinator had no misses.
The best policy to avoid missing MRD due to immunophenotypic
shifts may be to deﬁne, whenever possible, at least two different
LAPs. The performance of all centers to deﬁne a second LAP in
patients where such LAP had indeed been formulated at the
consensus meetings is shown in Figure 3b. In the learning phase,
such a second LAP was missed in 8–29% of patients by centers 2–5
and in 10% of patients by the coordinator. These percentages were
slightly lower in the test phase: a second LAP was missed in 9–20%
of patients by centers 2–5 and in 6% by the coordinator. Thus, in
addition to patients in which all LAPs had been missed (Figure 3a), a
second LAP may be missed in some instances, where a ﬁrst LAP had
been successfully identiﬁed (Figure 3b).
Types of missed LAPs. In a next analysis, we investigated which
types of LAPs are missed. LAPs missed by more than one center in
relatively high percentages were those with asynchronous antigen
expression (31–48%), with the exception of LAPs with an absence
of marker(s) (for example, CD133þCD34 , CD15HLA-DR ,
CD33 and HLA-DR ; see Table 3), LAPs with marker over-
expression (25–88%) and LAPs without immature markers
(14–50%) (Supplementary Table 2). The identiﬁcation of LAPs
with cross-lineage marker expression was generally most success-
ful (7–32% misses). Performance of the individual LAPs is shown in
Supplementary Table 3. Although, upon this further subdivision,
numbers become too low to reliably evaluate, institutes were
observed to perform well for the cross-lineage LAP with CD7, and
also for LAPs with aberrant absence of marker expression
(see above).
Irrespective of the type of LAP, it may be argued that the
sensitivity and speciﬁcity category may also affect the success of
identiﬁcation of a LAP. Figure 4 shows the results for sensitivity
only, because the speciﬁcity categories harbored too low numbers
for reliable conclusions. The main conclusion (details in
Supplementary Results) is that the centers performed much better
for high-sensitivity category compared with intermediate and low-
sensitivity category. However, substantial improvement was seen
from the learning phase to the test phase, ending with almost
similar performance in the high and intermediate category in the
test phase.
Incorrectly assigned LAPs. Although missed LAPs may prevent
evaluation of a patient’s MRD, incorrect assignment of a LAP may
result in unreliable assessments of MRD cell frequency. Incorrectly
designed LAPs mainly resulted from underestimation of back-
ground LAP expression in normal BM. In the learning phase,
Table 4. Percentages of missed LAPs by the different centers in learning and test phase
Phase Institute 1 Institute 2 Institute 3 Institute 4 Institute 5
Missed % Missed % Missed % Missed % Missed %
1 6/55 11 18/46 39 28/55 51 34/54 63 20/33 61
2 3/88 3 24/88 27 32/88 36 34/84 40 18/65 28
D  8  12  15  23  33
Abbreviation: LAP, leukemia-associated (immuno)phenotype. A LAP was noted as ‘missed’ in cases where a LAP had not been defined with the aberrant
marker agreed upon in the consensus LAP. Only institutes 1 and 3 evaluated all 64 samples, with a maximally reachable number of 143 LAPs. Institutes 2, 4 and
5 evaluated 59, 62 and 39 of the 64 samples, respectively. In the samples evaluated by these institutes, the maximally reachable number of LAPs was 134, 138
and 98, respectively, and percentages of missed LAPs were calculated using the latter numbers. ‘D’ indicates difference in % between learning phase (phase 1)
and test phase (phase 2). Differences between the two phases were significant: P¼ 0.015 (all institutes) and P¼ 0.022 for institutes 2–5.
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Figure 3. Missed consensus LAPs. For 63 of the 64 patients
reported here, at least one consensus LAP could be agreed upon.
Cases with no LAP defined for a particular institute and a particular
patient were scored as ‘missed patient’. Institutes 1–5 analyzed 29,
24, 29, 28 and 12 samples in the learning phase (gray bars) and 35,
35, 35, 34 and 27 samples in the test phase (black bars),
respectively. Panel a shows the proportions of patients in whom
no LAPS were defined and panel b shows the proportions of
patients in whom extra LAPs were missed. (a) For institutes 1–5,
percentages of patients who would not have been eligible for MRD
assessment are shown (no LAPs were defined, whereas at least one
consensus LAP was present). Improvement was 0%, 10%, 17%, 14%
and 26% for institutes 1–5, respectively. Differences between the
two phases were significant: P¼ 0.035 (all institutes: n¼ 5) and
P¼ 0.016 (institutes 2–5). (b) For institutes 1–5, the percentages of
patients in whom only one LAP was defined, whereas at least two
consensus LAPs were present, are shown. Only institute 2 had
made considerable improvement (20%). Note that this figure does
not include learning effects for all defined LAPs: these have been
shown earlier in Table 4. In that table, all institutes made
progression, which apparently is merely due to increased
performance in defining LAPs additional to the two defined for
Figure 3b.
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centers performed experiments on background staining in normal
BM and evaluated speciﬁcity. Speciﬁcity of LAPs was an important
issue at the consensus meetings. Incorrectly designed LAPs were
only scored as such during the test phase and are shown (per
sample and per institute) in Supplementary Figure 2 (green
symbols). The percentages of incorrectly designed LAPs were low
in institutes 1 and 2, but considerably higher in institutes 3 and 4.
The number of LAPs was too low for reliable conclusions for
institute 5. Such incorrect designs included the omission of
exclusion markers, incorrect interpretation of levels of expression
and deﬁnition of incorrect LAPs (for detailed information, see
Supplementary Results). No speciﬁc type of incorrectly designed
LAPs, common to all participants, could be deﬁned, except for the
fact that, for LAPs deﬁned by the absence of expression of
markers such as HLA-DR, inclusion of an exclusion marker is
recommended.
DISCUSSION
The current study was undertaken to establish criteria necessary to
enable assessment of MRD in clinical studies in a multicenter
setting. Such studies should establish whether or not MRD has the
prognostic value reported by several single-institute retrospective
studies, and at what time points and for which speciﬁc patient
groups MRD assessment can be a part of clinical decision making.
Such approach has in the meanwhile been applied in childhood
AML, although in a single-center approach.12
When deﬁning criteria to be fulﬁlled for a multicenter approach,
we deﬁned two distinct studies: ﬁrst, deﬁnition of LAP at diagnosis
and, second, the use of such LAPs to detect and quantify MRD
during follow-up. The present study deals with the diagnostic part.
Altogether, the ﬁnal success rate of deﬁning at least one
consensus LAP was high (only 1 out of 64 samples had no LAPs
at all), whereas in two-third of the samples two or more
independent consensus LAPs could be deﬁned. However, this
result was achieved after multiple analyses and extensive group
discussions and was based for a large part on the experience of
the coordinating center. The complexity to deﬁne LAPs by relatively
unexperienced centers is evidenced by the high percentages of
missed LAPs by centers 2–5, even in the second, testing phase. Some
cross-lineage aberrancies, as well as those asynchronous aberrancies
that are characterized by complete lack of a marker, were apparently
the easiest to deﬁne. Other asynchronous aberrancies, antigen
overexpression and aberrancies on mature cells were more difﬁcult
to establish. In addition, in the initial learning phase, the success rate
decreased with decreasing sensitivity (that is, represented by blast
coverage percentage of LAPs).
With time, a learning effect, evidenced by the success rate of
deﬁning LAPs, was seen. This result was partly because of the
thorough discussions at the group meetings. Ultimately, in the test
phase this resulted in a success rate (that is, at least one LAP
deﬁned) of 82–93% for the relatively inexperienced institutes 2–5
in the 35 evaluable samples. Improvement was especially evident
in a category with intermediate sensitivity; in the test phase, LAPs
were identiﬁed with equal success rate in the high-sensitivity and
the intermediate-sensitivity category. However, the overall results
implicate that, because of missed LAPs, 7–18% of the patients
would not have been evaluable for MRD according to these
centers.
Furthermore, in another 9–20% of cases, a center deﬁned only a
single LAP, whereas at least two LAPs were ﬁnally deﬁned in the
consensus meetings. These patients would be more likely to
become false negative for MRD if immunophenotypic shifts would
have occurred. It has been reported by others and by us5,11,16 that
such shifts occur frequently, although it has not always led to the
disappearance of markers. In case only one aberrant marker is
present, it is advised to design a second staining in which the
nonaberrant markers that are included in the LAP are replaced by
other, nonaberrant, markers. In this way, the risk of loss of these
normal markers, which could also result in false negativity, is
minimized. For example, a ‘primitive’ marker, CD133, may
occasionally become negative; replacement by, for example,
CD34 would then be adequate. This condition was met in the
current study because in 18% of cases at least two primitive
markers among CD34, CD133 and CD117 were present. In most
cases, it is possible to replace a myeloid marker by another. As the
expression of CD33, CD13 and CD117 is quite stable, the design of
the same LAPs with alternative myeloid markers is not urgent.
Our group had agreed that LAPs should cover at least 10% of
the blast cells at diagnosis: ﬁrst, because ‘background’ levels in
normal BM may amount to this percentage and, second, because
lower frequencies will signiﬁcantly hamper the sensitivity neces-
sary for MRD detection.
Another important factor for the quality of a LAP is speciﬁcity,
which is determined by LAP expression on control normal or
regenerating BM. Cell populations with the immunophenotype of
LAPs are present in frequencies varying from 0.001 to 0.1% in
control BM. In practice, the contribution of these ‘LAP-like’ events
to speciﬁc AML-derived, LAPþ cells will have to be deﬁned in the
setting of MRD. This interaction will strongly depend on the level
and intensity of expression of the aberrant markers on the normal
versus AML cell populations. AML cells at diagnosis may occupy
the so-called ‘empty spaces’—that is, positions of antigen
expression absent in normal cells; however, because of
even moderate immunophenotypic changes during or after
therapy, AML-speciﬁc LAPþ events may interfere with normal
LAPþ events. Even if stringent precautions have been taken to
standardize antibody–ﬂuorochrome combinations, as well as
instrumental setup and calibration over time, there is no
guarantee that the AML LAPþ population will not be ‘con-
taminated’ by normal events with ‘LAP-like’ immunophenotypes.
The impact of ‘background LAP’ on the reliable detection of
speciﬁc (AML) LAPþ events is considerable: up to 0.1% of WBC
and up to 10% of primitive marker compartment is possible; as a
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Figure 4. Performance of individual institutes in different sensitivity
categories in the learning and test phase. The figure shows the
performance of the four centers to define LAPs, now subdivided into
the three sensitivity categories (i.e., high (450%), black; intermedi-
ate (20–50%), dark gray; and low (10–20%), light gray). Missed LAPS
in a sensitivity category are expressed as percentage of the maximal
number of consensus LAPs defined in that specific sensitivity
category. In the learning phase, the percentage of missed LAPs was
significantly higher in the intermediate-sensitivity (marked *P¼ 0.01)
and in the low-sensitivity category (marked #P¼ 0.001) than in the
high-sensitivity category (all centers included). These differences
were also significant when the coordinating center (1) was excluded
from analysis (P-values ranging between 0.01 and 0.05). When
comparing the learning and test phases, for centers 2–5 there was
an improvement in the intermediate-sensitivity category (marked
zP¼ 0.016). There was also improvement in the lowest sensitivity
category (marked yP¼ 0.024).
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result, speciﬁc detection of MRD o0.1% is compromised
(Figure 2). On the basis of its very high background levels, at
the end of the learning phase, CD36 was concluded not to
represent a valuable marker for MRD.
The type of LAP and their distribution over patient groups differ
within the literature. In the present study, the frequency of LAPs
with asynchronous expression was twice as high as for cross-
lineage aberrancies, which is in agreement with some other adult
studies performed with these two types of major aberrancies.14
However, in two previous studies on adult AML5 and childhood
AML11 in which we were involved, the frequencies of both LAP
types were more or less equal.
Our study also indicated that MRD studies may be performed
using different instruments: in our case, four Becton Dickinson and
one Beckman Coulter (Miami, FL, USA) ﬂow cytometer were used.
This is of importance in view of international clinical studies in
which MRD assessment may be dealt with by (core) centers that
may use different brands of ﬂow cytometers.
The large differences in speciﬁcity, as well as LAP coverage on
blasts, represent a problem when cutoff levels have to be deﬁned
for clinical decision making: although in the case with high
speciﬁcity and high sensitivity, MRD levels of 0.01% (that is,
1:10 000) can be accurately measured, in other cases levels of only
0.1% or even lower may be the maximally reachable sensitivity.
Improvements can be expected from the use of more colors, as
shown by Voskova et al.13, in the transition from four to ﬁve colors.
The use of at least eight-color ﬂow cytometry, now feasible in
many institutes, will further improve ﬂow-cytometric MRD analysis.
The use of novel software tools (for example, Inﬁnicyt (Cytognos,
Salamanca, Spain)) for deﬁning LAPs in an objective manner may
further improve ﬂow-cytometric MRD analysis.
In conclusion, our study has shown that immunophenotypic
MRD assessment is a complex process that requires speciﬁc
experience that is not covered by a large experience in only
standard diagnostic immunophenotyping. The quality of MRD
assessment can only be guaranteed after a substantial period of
training under the guidance of highly experienced center(s).
Therefore, we recommend that, currently, the number of centers
that participate in large-scale multicenter MRD studies be
restricted to a few core centers with MRD experience.
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